Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479539 | 0.75 | HTT (0.39) | PRKCQALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL9010876 | 0.73 | MKNK1 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8965113 | 0.73 | PRKCQ (0.55) | PRKCQ | |
| SCHEMBL8969734 | 0.73 | PRKCQ (0.55) | PRKCQ | |
| SCHEMBL1481581 | 0.73 | HTT (0.37) | PRKCQKMT2A | |
| SCHEMBL8964806 | 0.73 | GBA1 (0.36) | JAK3 | |
| SCHEMBL8964814 | 0.73 | CHRM2 (0.45) | OPRK1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8964816 | 0.72 | PRKCQ (0.52) | OPRK1PRKCQ | |
| SCHEMBL19522483 | 0.71 | OPRK1 (0.44) | OPRK1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL9011525 | 0.71 | PRKCQ (0.53) | OPRK1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | OPRK1 1228/4885JAK3 171/4885LCK 54/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | OPRK1 1228/4885JAK3 171/4885LCK 54/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | OPRK1 1228/4885JAK3 171/4885LCK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.